Literature DB >> 27020495

The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma.

Meiping Lu1, Huijun Zhu2, Xudong Wang3, Dawei Zhang4, Lin Xiong5, Li Xu6, Yiwen You7.   

Abstract

Eg5 is identified as a microtubule-dependent motor protein and has been suggested to play important role in cancer development. The aim of this study was to detect the expression of Eg5 and its clinicopathological characteristics in patients with laryngeal squamous cell carcinoma. One-step quantitative reverse transcription-polymerase chain reaction (qPCR) test with 20 fresh-frozen LSCC samples and immunohistochemistry (IHC) analysis in 137 LSCC cases were performed to investigate the relationship between Eg5 expression and the clinicopathological characteristics of LSCC. The Eg5 mRNA and protein levels were significantly higher in LSCC tissues compared with corresponding non-cancerous tissues (p < 0.05). Eg5 protein expression was significantly correlated to lymph node metastasis (p = 0.021) and TNM stage (p = 0.030). Kaplan-Meier survival and multivariate analysis with Cox regression model indicated that high Eg5 expression (p = 0.031) and TNM stage (p = 0.011) were independent factors to predict unfavourable prognosis for patients with LSCC. The data suggested that Eg5 may be identified as a novel prognostic biomarker and targeting Eg5 seems to be a novel strategy for LSCC treatment.
Copyright © 2016 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Eg5; IHC; LSCC; qPCR

Mesh:

Substances:

Year:  2016        PMID: 27020495     DOI: 10.1016/j.pathol.2016.02.008

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  8 in total

1.  Screening and expression verification of key genes in cutaneous squamous cell carcinoma.

Authors:  Shuting Huang; Si Qin; Ju Wen; Yangfan Zhou; Zhenyu Lu
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

2.  Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.

Authors:  Bruna Cândido Guido; Douglas Cardoso Brandão; Ana Luisa Augusto Barbosa; Monique Jacob Xavier Vianna; Lucas Faro; Luciana Machado Ramos; Fabíola Nihi; Márcio Botelho de Castro; Brenno A D Neto; José Raimundo Corrêa; Sônia Nair Báo
Journal:  Oncotarget       Date:  2021-09-14

3.  Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Can Liu; Nan Zhou; Jieying Li; Jun Kong; Xi Guan; Xudong Wang
Journal:  Dis Markers       Date:  2017-06-08       Impact factor: 3.434

4.  Cancer drug therapy and stochastic modeling of "nano-motors".

Authors:  Lubna Sherin; Shabieh Farwa; Ayesha Sohail; Zhiwu Li; O Anwar Bég
Journal:  Int J Nanomedicine       Date:  2018-10-15

5.  KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.

Authors:  Zhan-Dong Hu; Ying Jiang; Hong-Mei Sun; Jing-Wen Wang; Li-Li Zhai; Zhi-Qi Yin; Jun Yan
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

6.  Effect of N-1 arylation of monastrol on kinesin Eg5 inhibition in glioma cell lines.

Authors:  Itamar Luís Gonçalves; Liliana Rockenbach; Gustavo Machado das Neves; Gabriela Göethel; Fabiana Nascimento; Luciano Porto Kagami; Fabrício Figueiró; Gabriel Oliveira de Azambuja; Amanda de Fraga Dias; Andressa Amaro; Lauro Mera de Souza; Ivan da Rocha Pitta; Daiana Silva Avila; Daniel Fábio Kawano; Solange Cristina Garcia; Ana Maria Oliveira Battastini; Vera Lucia Eifler-Lima
Journal:  Medchemcomm       Date:  2018-04-17       Impact factor: 3.597

7.  High Eg5 expression predicts poor prognosis in breast cancer.

Authors:  Qin Jin; Fang Huang; Xudong Wang; Huijun Zhu; Yun Xian; Jieying Li; Shu Zhang; Qichao Ni
Journal:  Oncotarget       Date:  2017-07-10

8.  Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme.

Authors:  Bao-Shi Chen; Kuan-Yu Wang; Shu-Qing Yu; Chuan-Bao Zhang; Guan-Zhang Li; Zhi-Liang Wang; Zhao-Shi Bao
Journal:  Oncol Lett       Date:  2020-09-03       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.